Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
483 Preclinical evaluation of JTX-1484, an anti-LILRB4 antagonist antibody, for re-programming of immunosuppressive myeloid cells
Compose a Response to This Article
Other responses
No responses have been published for this article.